Bio-Path Holdings Reports Third Quarter 2021 Financial Results
November 12, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021
November 05, 2021 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting
November 04, 2021 09:01 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
October 27, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
August 24, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
August 13, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021
August 06, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003
June 22, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings Reports First Quarter 2021 Financial Results
May 14, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 14, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021
May 07, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...